Kissei gains Japanese rights to Vifor's hyperphosphataemia agent
This article was originally published in Scrip
Kissei has acquired Japanese rights to Vifor Pharma's iron oxyhydroxide product PA21 for the treatment of hyperphosphataemia in chronic renal failure patients undergoing dialysis.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.